ProKidney Corp/$PROK
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About ProKidney Corp
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
Ticker
$PROK
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
204
ISIN
US74291D1046
Website
ProKidney Corp Metrics
BasicAdvanced
$579M
-
-$0.60
1.58
-
Price and volume
Market cap
$579M
Beta
1.58
52-week high
$7.13
52-week low
$0.55
Financial strength
Current ratio
10.963
Quick ratio
10.066
Long term debt to equity
0.679
Total debt to equity
0.911
Interest coverage (TTM)
-25,666.29%
Profitability
EBITDA (TTM)
-173.734
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-22,362.09%
Operating margin (TTM)
-58,713.73%
Effective tax rate (TTM)
0.06%
Management effectiveness
Return on assets (TTM)
-28.29%
Return on equity (TTM)
-45.28%
Valuation
Price to revenue (TTM)
1,630.353
Price to book
-0.56
Price to tangible book (TTM)
-0.56
Price to free cash flow (TTM)
-3.303
Free cash flow yield (TTM)
-30.27%
Free cash flow per share (TTM)
-131.38%
Growth
Earnings per share change (TTM)
3.86%
3-year earnings per share growth (CAGR)
-3.65%
Bulls say / Bears say
ProKidney Corp. reported statistically and clinically significant topline results for the Phase 2 REGEN-007 trial evaluating rilparencel in patients with chronic kidney disease and diabetes, indicating potential efficacy of their lead product. (stocktitan.net)
The company announced strategic updates to its Phase 3 program to accelerate rilparencel’s registrational path to potential approval in the U.S., potentially reducing expenses by $150-$175 million and extending the cash runway into Q1 2027. (stocktitan.net)
ProKidney completed its domestication from the Cayman Islands to Delaware, which may enhance corporate governance and appeal to U.S. investors. (globenewswire.com)
ProKidney's net income for the trailing twelve months is reported at -$163.34 million, indicating significant financial losses. (stocktitan.net)
The company's operating cash flow stands at -$126.35 million, reflecting substantial cash outflows from operations. (stocktitan.net)
ProKidney's net profit margin is -214,914.47%, highlighting severe profitability challenges. (stocktitan.net)
Data summarised monthly by Lightyear AI. Last updated on 11 Jul 2025.
ProKidney Corp News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ProKidney Corp stock?
ProKidney Corp (PROK) has a market cap of $579M as of July 11, 2025.
What is the P/E ratio for ProKidney Corp stock?
The price to earnings (P/E) ratio for ProKidney Corp (PROK) stock is 0 as of July 11, 2025.
Does ProKidney Corp stock pay dividends?
No, ProKidney Corp (PROK) stock does not pay dividends to its shareholders as of July 11, 2025.
When is the next ProKidney Corp dividend payment date?
ProKidney Corp (PROK) stock does not pay dividends to its shareholders.
What is the beta indicator for ProKidney Corp?
ProKidney Corp (PROK) has a beta rating of 1.58. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.